Navigation Links
Glenmark's Consolidated Revenue Increases by 20.08% to Rs. 14,869.40 Mn for Q1 FY 14 - 15

MUMBAI, India, July 24, 2014 /PRNewswire/ --

Consolidated Net Profit increased by 43.65 % to Rs. 1848.46 Mn

Business Highlights  

  • India Business grew by 20.87% to Rs. 3,971.59 Mn
  • US Business grew by 9.33% to Rs. 4,886.70 Mn
  • Rest of World (ROW) Business grew by 20.67% to Rs. 2,113.09 Mn
  • Europe Formulations Business grew by 34.53% to Rs. 977.26 Mn
  • Latin America Business grew by 33.92% to Rs. 1,176.45 Mn

Glenmark Pharmaceuticals Limited, the research-led global integrated pharmaceutical company, today announced its results for the first quarter ended June 30, 2014.


For the first quarter ended June 30, 2014, Glenmark's consolidated revenue was at Rs. 14,869.40 Mn (USD 248.61 Mn) as against Rs. 12,382.43 Mn (USD 221.91 Mn) in the corresponding quarter recording a growth of 20.08%. Consolidated EBITDA grew by 38.16% to Rs. 3423.32 Mn from Rs. 2477.82 Mn in the quarter. The consolidated Net Profit was at Rs. 1848.46 Mn for the quarter ended June 30, 2014 as compared to Rs. 1286.76 Mn for the previous corresponding quarter registering an increase of 43.65%.

"We have delivered strong results backed by good performances by our India, Rest of the World, Europe and LATAM businesses. While we outperformed in the Indian Pharmaceutical market with a growth of over 20%; our Rest of the World business led by Russia and LATAM operations bounced back strongly in this quarter with growth rates of over 20% and 30%  respectively"; said Glenn Saldanha, Chairman & MD, Glenmark Pharmaceuticals Limited. "We have been making steady progress in our innovation pipeline and now have three first-in-class monoclonal antibodies (mAb) in clinical development. It is encouraging to note that very few companies around the world have three first-in-class mAbs in clinical development. The inauguration of a new monoclonal antibody manufacturing facility in Switzerland was an important development during this quarter which now gives us end-to-end capabilities for the discovery and development of novel monoclonal antibodies"; he added.

India Formulations 

Sales for the formulation business in India for the first quarter ended June 30, 2014, was at Rs. 3,971.59 Mn (USD 66.40 Mn) as against Rs. 3,285.83 Mn (USD 58.89 Mn) in the previous corresponding quarter, recording a growth of 20.87%.

USA Formulations 

Glenmark Generics Inc., U.S.A. registered revenue from the sale of finished dosage formulations was Rs. 4,886.70 Mn (USD 81.70 Mn) for the quarter ended June 30, 2014 as against revenue of Rs. 4,469.52 Mn (USD 80.10 Mn) for the previous corresponding quarter, recording an increase of 9.33%.

Africa, Asia and CIS Region (ROW)  

For the first quarter, revenue from Africa, Asia and CIS region was Rs. 2,113.09 Mn (USD 35.33 Mn) as against Rs. 1,751.20 Mn (USD 31.38 Mn) for the previous corresponding quarter, recording an increase of 20.67%.

Europe Formulations 

Glenmark Europe's operations revenue for the first quarter ended June 30, 2014 was at Rs. 977.26 Mn (USD 16.34 Mn) as against Rs. 726.45 Mn (USD 13.02 Mn) recording growth of 34.53%.

Latin America 

Glenmark's revenue from its Latin American and Caribbean operations was at Rs. 1,176.45 Mn (USD 19.67 Mn) for the first quarter ended June 30, 2014 as against Rs. 878.49 Mn (USD 15.74 Mn) an increase of 33.92%.

Active Pharmaceutical Ingredients (API) 

Revenue from sale of API to regulated and semi-regulated markets globally was Rs. 1,445.26 Mn (USD 24.16 Mn), for the quarter ended June 30, 2014 against Rs. 1,270.94 Mn (USD 22.78 Mn) for the previous corresponding quarter, recording an increase of 13.72%.

About Glenmark  

Glenmark Pharmaceuticals Ltd. (GPL) is a research-driven, global, integrated pharmaceutical company headquartered at Mumbai, India. It is ranked among the top 80 Pharma & Biotech companies of the world in terms of revenues. (SCRIP 100 Rankings published in the year 2013). Glenmark is a leading player in the discovery of new molecules both NCEs (new chemical entity) and NBEs (new biological entity). Glenmark has several molecules in various stages of clinical development and is primarily focused in the areas of Inflammation [asthma/COPD, rheumatoid arthritis etc.] and Pain [neuropathic pain and inflammatory pain].

The company has a significant presence in branded generics markets across emerging economies including India. GPL along with its subsidiary has 14 manufacturing facilities in four countries and has six R&D centers. Its subsidiary, Glenmark Generics Limited services the requirements of the US and Western Europe generics markets. The API business sells its products in over 80 countries, including the US, various countries in the EU, South America and India.

For further information, please contact:
Jason D'Souza / Rajdeep Barooah
Glenmark Pharmaceuticals Ltd.
Tel: [+91-22]-40189919/984

SOURCE Glenmark Pharmaceuticals
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. Glenmarks Consolidated Revenue Increases by 18.9% to Rs. 12551.9 Mn for Q2 FY12-13
2. Glenmarks Consolidated Revenue Increases by 33.96% to Rs. 13812.59 Million for Q3 FY 12-13
3. PipelineRx Completes Acquisition of Healthcare Connectivity Solutions Company Evolute Consolidated Holdings
4. Kelyniam Global Inc. Reports Record Cranial Implant Revenues in the 1st Quarter of 2012
5. CryoLife Reports Record Quarterly Revenues in First Quarter of 2012
6. Aethlon Medical Note: Fiscal Year Revenue Guidance
7. Bacterin Announces First Quarter 2012 Revenue of $7.8 Million, Up 29% Year-over-Year, on Gross Margins of 76%, and 34% Reduction in Operating Loss
8. Perrigo Reports Record Third Quarter Revenue And Earnings And Raises Full Year EPS Guidance
9. SynCardia Posts Record Revenue and Profit in Q1 2012
10. Auxilium Pharmaceuticals, Inc. Raises Revenue Guidance And Reduces Net Loss Guidance For 2012
11. InfuSystem Holdings, Inc. Reports $14.3 Million of Revenues And $1.6 Million Of EBITDA For The First Quarter Of 2012
Post Your Comments:
(Date:10/9/2015)... , Oct. 9, 2015  Impax Laboratories, Inc. ... will release its third quarter 2015 financial results on ... the U.S. financial markets. The Company will host a ... at 8:30 a.m., Eastern Time on November 9, 2015.  ... . --> The financial results and live ...
(Date:10/9/2015)... Eli Lilly and Company (NYSE: LLY ) ... 50 new jobs to its research and development presence at ... New York . --> ... include a translational immuno-oncology hub and a Lilly "portal," which ... to cutting-edge drug discovery capabilities, including chemistry and lead optimization ...
(Date:10/9/2015)... Switzerland , October 9, 2015   ... with KUR-111 meets primary efficacy endpoint San Diego, ... Orthopaedics and Chief of Orthopaedic Trauma, NYU Lutheran Medical Center, on ... San Diego, California , by Dr. Tom Lyon ... Medical Center, on 9 th October 2015 at 8:30a.m. PDT. ...
Breaking Medicine Technology:
... PDII ) today announced that Nancy Lurker, the company,s chief executive ... Services Conference at 8:30 am ET on February 7, 2012 at The ... webcast may be accessed under the "Investor Relations" tab on the company,s ... days. About PDI, Inc. PDI ...
... 2012  The IP & Science business of Thomson ... for Applied Economic Research (IPEA). This partnership provides ... Innovation, Regulation and Infrastructure (DISET) branch with access ... supplying them with generic pharmaceutical intelligence as well ...
Cached Medicine Technology:
(Date:10/10/2015)... ... October 10, 2015 , ... The Bank of America 500 NASCAR Sprint Cup ... Saturday, October 10th, defending race winner, Kevin Harvick, will battle it out for the ... and all of the stars of the NASCAR Sprint Cup Series. As part ...
(Date:10/10/2015)... ... October 10, 2015 , ... In the inaugural people’s choice contest, entitled Bold ... Work in Jacksonville, amongst medium-sized companies with 25 – 99 employees. The announcement was ... a celebratory gala on October 1st. , Many of the features of the ...
(Date:10/9/2015)... ... October 09, 2015 , ... With the FCPX LUT Vibrance pack ... footage. A LUT is a Lookup Table that contains a mathematical formula for modifying ... the table. This pack comes with 60 vibrant CUBE LUT files. , ...
(Date:10/9/2015)... CA (PRWEB) , ... October 09, 2015 , ... ... now offering a special promotion on Invisalign, the orthodontic system that uses clear, ... The aligners are almost invisible against the teeth, which allow patients to complete ...
(Date:10/9/2015)... ... 09, 2015 , ... Confidence Plus Insurance has just celebrated ... initiative that involves working with a series of local charities throughout the California ... Insurance is the Gleason Park Electric Violin Ensemble (GPEVE). , GPEVE provides a ...
Breaking Medicine News(10 mins):
... , New Report Highlights Best and Worst State ... Va., Sept. 10 A new report by The Vision Council, ... for children entering school are inconsistent, impeding children,s ability to succeed ... visual processing of information, undetected vision problems can severely impact a ...
... largest network of Hispanic health advocates joins President Obama,s efforts to improve ... , WASHINGTON, Sept. 9 "There was a clear ... reform. We need to work together to get the job done and ... our history, it is essential that we do this to support America,s ...
... , Statement attributable to: J. James Rohack, M.D. President, ... that Medical Liability Reform is Needed , , ... is unacceptable. The AMA will continue to work for reform that makes ... opportunity this year to achieve meaningful health reform for America,s patients and ...
... Sept. 9 In commemoration of the first September 11 National ... Los Angeles will host three 2-hour volunteer orientations for 100+ youth and ... tour of the chapter,s new state of the art Emergency Operation Center, ... recent California wildfires. , , What: ...
... MECHANICSBURG, Pa., Sept. 9 Select Medical Holdings ... the launch of its initial public offering of 33,333,333 shares ... is expected to be between $11.00 and $13.00 ... of common shares by Select, and Goldman, Sachs & Co., ...
... 9 As the nation awaits President Obama,s address on ... Philanthropic Collaborative (TPC) sent today a letter to the President ... foundations in the field of health. , , ... the social and economic effectiveness of health-related philanthropic activities. ...
Cached Medicine News:
CDIs new improved Implant Stabilizer has super-soft elastic bands with lace trim....
Bras and Breast Support...
Post-Surgical compression garments...
... The Albumin Cobalt Binding (ACB®) Test is ... Modified Albumin (IMA®) by measuring the cobalt ... serum sample. First identified in the early ... comes in contact with ischemic tissue in ...
Medicine Products: